Yanjie Wu

Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309)

Yunpeng Yang, Jianji Pan, Hui Wang et al. · Cancer Cell · 2023 · 191 citations · Full text

R/m Npc, Immunology, Pathology +16

Sonodynamic Therapy of NRP2 Monoclonal Antibody‐Guided MOFs@COF Targeted Disruption of Mitochondrial and Endoplasmic Reticulum Homeostasis to Induce Autophagy‐Dependent Ferroptosis

Zhiyu Zhao, Yanjie Wu, Xiaochen Liang et al. · Advanced Science · 2023 · 65 citations · Full text

A Phase 2 Study of Tislelizumab in Combination With Platinum-Based Chemotherapy as First-line Treatment for Advanced Lung Cancer in Chinese Patients

Zhijie Wang, Jun Zhao, Zhiyong Ma et al. · Lung Cancer · 2020 · 62 citations · Full text

RATIONALE-309: Updated progression-free survival (PFS), PFS after next line of treatment, and overall survival from a phase 3 double-blind trial of tislelizumab versus placebo, plus chemotherapy, as first-line treatment for recurrent/metastatic nasopharyngeal cancer.

Li Zhang, Yunpeng Yang, Jianji Pan et al. · Journal of Clinical Oncology · 2022 · 27 citations

Progression-free Survival, Tislelizumab Versus Placebo, Immunology +19

Ultrasound-activated erythrocyte membrane-camouflaged Pt (II) layered double hydroxide enhances PD-1 inhibitor efficacy in triple-negative breast cancer through cGAS-STING pathway-mediated immunogenic cell death

Yanjie Wu, Zhiyu Zhao, Mengli Ma et al. · Theranostics · 2024 · 15 citations · Full text